Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QRX003 Lotion in Subjects With Netherton Syndrome
NCT05521438Phase 3Active, not recruiting
- Sponsor
- Quoin Pharmaceuticals Ltd.
- Start
- Jun 2022
- Primary completion
- Dec 2025
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QRX003 in Netherton syndrome (NS) (4 arms), sponsored by Quoin Pharmaceuticals Ltd. Primary endpoints: 1-point Investigator's Global Assessment, 2-point Investigator's Global Assessment and 7 more. Started Jun 2022; status: active, not recruiting.
02
Drugs
QRX003
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on NCT05521438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521438.